Intellia Therapeutics
NTLA
371 hedge funds and large institutions have $7.59B invested in Intellia Therapeutics in 2021 Q4 according to their latest regulatory filings, with 66 funds opening new positions, 126 increasing their positions, 118 reducing their positions, and 55 closing their positions.
20% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 55
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
2% more funds holding
Funds holding: 364 → 371 (+7)
1.65% more ownership
Funds ownership: 84.63% → 86.28% (+1.6%)
7% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 118
9% less capital invested
Capital invested by funds: $8.34B → $7.59B (-$748M)
28% less call options, than puts
Call options by funds: $44.1M | Put options by funds: $61.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$147M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.4M |
| 3 |
Morgan Stanley
New York
|
+$47.3M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$44.3M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$44.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$49.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$33.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$30.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$24.3M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$22.2M |
NTLA Hedge Fund Activity: Q4 2021 in Review
371 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2021, worth a combined $7.59B — down 9% from $8.34B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new NTLA positions and 55 closed out — a net gain of 11 holders — while 126 added to existing stakes and 118 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $147M. The largest seller was Temasek Holdings, cutting an estimated $49.8M.
- 371 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2021, up from 364 in Q3 2021.
- Funds reported $7.59B of Intellia Therapeutics stock for Q4 2021, down 9% quarter-over-quarter.
- 66 funds opened new Intellia Therapeutics positions in Q4 2021 and 55 closed out, a net change of +11 holders.
- The largest Intellia Therapeutics buyer in Q4 2021 was ARK Investment Management, an estimated $147M added.
- The largest Intellia Therapeutics seller in Q4 2021 was Temasek Holdings, an estimated $49.8M sold.
Based on aggregated 13F filings for Q4 2021.